Anchorage, Alaska 98508

  • Tubular Breast Carcinoma

Purpose:

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.


Study summary:

PRIMARY OBJECTIVES: I. To evaluate whether the reconstruction complication rate at 24 months post radiation is non-inferior with hypofractionation. SECONDARY OBJECTIVES: I. To evaluate the incidence of acute and late radiation complications, based on Common Terminology Criteria for Adverse Events (CTCAE) 4.0 toxicity. II. To evaluate the local and local regional recurrence rate. III. To compare reconstruction complication rates based on reconstruction method (autologous +/- implant versus [vs] implant only) and timing of reconstruction received (immediate vs. intent for delayed). TERTIARY OBJECTIVES: I. To evaluate reconstructed breast photographic cosmetic scores with hypofractionated radiation compared to standard fractionation 24 months after radiation. II. To evaluate reconstructed breast photographic cosmetic scores 24 months after radiation based on the method and timing of reconstruction received. III. To estimate the incidence of arm lymphedema by treatment arm. IV. To compare physical well-being, psychosocial well-being, sexual well-being, satisfaction with breast/nipples/abdomen, and satisfaction with overall outcome between the treatment arms at 24 months after radiation. V. To estimate patient satisfaction with trial participation by treatment arm as measured by the Was It Worth It Questionnaire at 24 months after radiation. VI. To compare the direct and indirect patient costs for radiation therapy by treatment arm. VII. To compare patient reported total health care service utilization 12 months after the completion of radiation. VIII. To compare the economic impact of treatment. IX. To analyze polymorphisms in MDM2 and in genes including TP53, ATM, TGFB1, IL4, IL6, and IL10 and determine correlations with a higher likelihood of adverse radiation reactions (radiation sensitivity) and with toxicities. X. To analyze polymorphisms in MDM2 and in genes including TP53, ATM, TGFB1, IL4, IL6, and IL10 to determine correlations with secondary endpoints such as local-regional control. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks. GROUP II: Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks. After completion of study, patients are followed up for 5 years.


Criteria:

Inclusion Criteria: - Histologically confirmed invasive carcinoma of the breast of any of the following histologies (ductal, lobular, mammary, medullary, or tubular); patients with metaplastic breast cancer are not eligible - Patients will be staged according to the TNM staging system - For patients not receiving neoadjuvant chemotherapy, pathologic staging must be T0N1-2a, T1N1-2a, T2N1-2a, T3N0-2a, and all M0 status - For patients receiving neoadjuvant chemotherapy, clinical pre-chemo staging and post mastectomy pathological staging is required for all patients; patients who have received neoadjuvant chemotherapy and are pathologically cT0-2 and N0 are only eligible if biopsy-proven clinically N1 or N2 disease is documented prior to the start of neoadjuvant chemotherapy; cT3N0 patients or ypT3N0 patients who receive neoadjuvant chemotherapy may be eligible based on clinical or pathological T stage, and do not require pathologically positive lymph nodes - Note: Higher of the clinical or pathological T and N stage are used for final staging, if receiving neoadjuvant chemotherapy; all patients with clinical, radiographic or pathological T4, N3 or involved internal mammary disease (N1b, N1c, and N2b) are not eligible. N1mic patients are eligible. - No prior therapeutic radiation therapy to the chest, neck or axilla; prior radioactive oral iodine is permitted - No prior history of ipsilateral breast cancer (invasive disease or ductal breast carcinoma in situ [DCIS]); lobular carcinoma in situ (LCIS) and benign breast disease is allowed - No history of prior or concurrent contralateral invasive breast cancer; benign breast disease, LCIS or DCIS of contralateral breast is allowed - No active collagen vascular diseases, such as: systemic lupus erythematous, scleroderma, or dermatomyositis - Negative inked histologic margins from mastectomy pathology (no invasive cells at margin). Patients with DCIS at margin are eligible. - No significant post mastectomy complications in the ipsilateral breast requiring an unplanned re-operation or admission for intravenous (IV) antibiotics; re-operation for margins evaluation, nodal completion and routine reconstruction is acceptable - Radiation oncologist intends to treat all target volumes and respect all normal tissues in accordance with the dosimetric constraints described (simulation before registration recommended) - Radiation oncologist is planning to treat regional lymph nodes including internal mammary nodes and meet acceptable protocol dosimetric requirements - Radiation oncologist is NOT planning to utilize a chest wall/scar boost - Patient must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 18 months after radiation - Treating physician and patient must plan to start radiation treatment within the timeframes specified in protocol. - If a tissue expander is utilized it needs to be a fluid filled expander, NO air expander (unless completely deflated) during radiation therapy - For patients with diabetes, hemoglobin A1C test must have been performed =< 90 days prior to registration - No co-existing medical conditions with life expectancy < 5 years - No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix - Negative pregnancy test (serum or urine HCG) in women of child-bearing potential ≤ 7 days prior to registration. Patients who have received a bilateral tubal ligation still require a negative pregnancy test for eligibility. A female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy and has not been naturally postmenopausal for at least 12 consecutive months - Women of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapy - Eastern Cooperative Oncology Group (ECOG) (Zubrod) performance status 0-1 - Patients must be able to read and comprehend English, in order to be able to complete study questionnaires; however, patients participating through Canadian Cancer Trials Group (CCTG) institutions who can read and comprehend French are eligible


Study is Available At:


Original ID:

A221505


NCT ID:

NCT03414970


Secondary ID:

NCI-2017-00817


Study Acronym:


Brief Title:

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer


Official Title:

RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction


Overall Status:

Active, not recruiting


Study Phase:

Phase 3


Genders:

N/A


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Alliance for Clinical Trials in Oncology


Oversight Authority:

There was an error processing this request


Reasons Why Stopped:


Study Type:

Interventional


Study Design:


Number of Arms:

2


Number of Groups:

0


Total Enrollment:

897


Enrollment Type:

Actual


Overall Contact Information

Official Name:Matthew Poppe, MD
Study Chair
Huntsman Cancer Hospital, University of Utah

Study Dates

Start Date:February 1, 2018
Completion Date:August 2035
Completion Type:Anticipated
Primary Completion Date:August 2023
Primary Completion Type:Anticipated
Verification Date:October 2021
Last Changed Date:October 1, 2021
First Received Date:January 17, 2018

Study Outcomes

Outcome Type:Primary Outcome
Measure:Rate of breast reconstruction complications
Time Frame:At 24 months
Safety Issues:False
Description:Will be tested using a two-sample test of proportions. The test statistic will be calculated and interim analysis for futility will be performed. The primary analyses will be an intent-to-treat analysis where all patients randomized will be included in th
Outcome Type:Secondary Outcome
Measure:Incidence of acute and late radiation complications based on Common Terminology Criteria for Adverse Events 4.0 toxicity
Time Frame:Up to 5 years
Safety Issues:False
Description:The proportion of patients with acute or late radiation complications, will be estimated separately by treatment arm and will be compared across the two arms using two-sample test of proportions (Z test) with a two-sided alternative.
Outcome Type:Secondary Outcome
Measure:Local and local regional recurrence
Time Frame:Up to 5 years
Safety Issues:False
Description:The cumulative incidence of local and local regional recurrence will be estimated separately by treatment arm using the cumulative incidence function treating death as the competing risk and will be compared using Gray's test.
Outcome Type:Secondary Outcome
Measure:Local and local regional recurrence-free survival
Time Frame:Up to 5 years
Safety Issues:False
Description:Local and local regional recurrence free survival will be summarized for each arm using the Kaplan-Meier estimators, and will be compared using a log rank test.
Outcome Type:Secondary Outcome
Measure:Reconstruction complication rates based on reconstruction method (autologous +/- implant versus [vs.] implant only) and timing of reconstruction received (immediate vs. intent for delayed)
Time Frame:Up to 5 years
Safety Issues:False
Description:Between-arm differences in reconstruction complication rates will be assessed separately within each of the six subgroups based on type and timing of reconstruction. Between-arm differences in complication rates will also be assessed within the two broade
Outcome Type:Secondary Outcome
Measure:Reconstructed breast photographic cosmetic scores
Time Frame:At 24 months
Safety Issues:False
Description:Two year photographic cosmetic scores will be summarized by treatment arm and will be compared across the treatment arms using a Wilcoxon rank-sum test with a two-sided alternative. The proportions of patients with poor global cosmetic score (defined as a
Outcome Type:Secondary Outcome
Measure:Reconstructed breast photographic cosmetic scores based on the method and timing of reconstruction received
Time Frame:At 24 months
Safety Issues:False
Description:Two year photographic cosmetic scores and the proportions of patients with poor global cosmetic score will be assessed separately by timing and method of reconstruction subgroups using similar method described above.
Outcome Type:Secondary Outcome
Measure:Incidence of arm lymphedema as measured by percent change in ipsilateral arm volume post-radiation from its pre-radiation volume
Time Frame:Up to 5 years
Safety Issues:False
Description:The proportions of patients with arm lymphedema (defined as a change of 10% or greater in ipsilateral arm volume from the pre-radiation therapy [RT] volume) at 2 year post radiation will be summarized and will be compared across the two treatment arms usi
Outcome Type:Secondary Outcome
Measure:Physical well-being, psychosocial well-being, sexual well-being, satisfaction with breast/nipples/abdomen, and satisfaction with overall outcome
Time Frame:At to 24 months
Safety Issues:False
Description:Change in Lymphedema and Breast Cancer Questionnaire and Breast Lymphedema scores at 24 months post-radiation (relative to pre-RT) and patient satisfaction scores as measured by the Breast Questionnaire overall outcome scale will be summarized and will be
Outcome Type:Secondary Outcome
Measure:Patient satisfaction with trial participation by treatment arm as measured by the Was It Worth It Questionnaire
Time Frame:At 24 months
Safety Issues:False
Description:Was It Worth It questionnaire responses to each of the five questions at 24 months will be summarized and the will be compared across treatment arms using a chi-square tests with a two-sided alternative.
Outcome Type:Secondary Outcome
Measure:Economic analyses
Time Frame:Up to 5 years
Safety Issues:False
Description:Direct costs of medical care to each patient will be estimated using utilization information from the health care expense survey and the health care utilization survey, along with publicly available Medicare reimbursement rates. In particular, based on th

Study Interventions

Intervention Type:Radiation
Name:Hypofractionated Radiation Therapy
Description:Undergo hypofractionated RT
Arm Name:Group II (hypofractionated radiation therapy)
Intervention Type:Other
Name:Laboratory Biomarker Analysis
Description:Correlative studies
Arm Name:Group I (radiation therapy)
Intervention Type:Other
Name:Quality-of-Life Assessment
Description:Ancillary studies
Arm Name:Group I (radiation therapy)
Intervention Type:Other
Name:Questionnaire Administration
Description:Ancillary studies
Arm Name:Group I (radiation therapy)
Intervention Type:Radiation
Name:Radiation Therapy
Description:Undergo RT
Arm Name:Group I (radiation therapy)

Study Arms

Study Arm Type:Experimental
Arm Name:Group II (hypofractionated radiation therapy)
Description:Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
Study Arm Type:Active Comparator
Arm Name:Group I (radiation therapy)
Description:Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Alliance for Clinical Trials in Oncology
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: February 03, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.